Chemomab Therapeutics has enrolled the first subject in its Phase IIa study of humanised monoclonal antibody CM-101 in Non-Alcoholic Steatohepatitis (NASH) patients.

A first-in-class antibody CM-101 can potentially attach to and hinder CCL24 activity, a vital chemokine activity that causes inflammation and fibrosis development.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multi-centre, randomised, double-blind, placebo-controlled, multiple-dose study will analyse the mechanism of action, safety, pharmacokinetics and pharmacodynamic effects, and the anti-fibrotic effects of subcutaneous CM-101 in NASH patients with fibrosis stage F2-F3.

It will enrol 40 subjects and is expected to conclude enrolment by the end of this year with results anticipated in the first half of next year.

In the study, subjects will be given eight subcutaneous doses of CM-101 every two weeks for 14 weeks. They will be evaluated for serum fibrotic and fibrolysis markers, serum inflammatory markers, liver fat content, and liver stiffness.

Chemomab CEO Dr Adi Mor said: “We are excited to initiate this Phase IIa study of CM-101 in NASH, one of our three Phase II studies for CM-101.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Data from this study will help validate our subcutaneous delivery of CM-101 and, if successful, the subcutaneous formulation has the potential to be used in our registrational trials for primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).”

In February this year, Chemomab had enrolled the first subject in a Phase IIa SPRING trial of CM-101 for treating PSC patients.

This multi-centre, double-blind, placebo-controlled study was designed to assess the safety and efficacy profile of CM-101 in adult participants with PSC for 15 weeks.

The company plans to commence an additional Phase II trial of the antibody for SSc treatment in the second half of this year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact